AIM ImmunoTech Inc. announced the completion of enrollment in the company's Phase 2 study evaluating Ampligen(R) as a potential therapeutic for people with post-COVID conditions ("AMP-518"). The study has met the planned enrollment of 80 AMP-518 subjects ages 18 to 60 years who have been randomized 1:1 to receive twice-weekly intravenous infusions of Ampligen or placebo for 12 weeks, with a follow-up phase of two weeks. The ompany expects to complete dosing of the last study patient in Fourth Quarter 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4 USD | -8.38% | -1.19% | -9.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.07% | 19.96M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions